恒瑞医药：关于获得药品注册批准的公告

Core Viewpoint - Heng Rui Medicine has received conditional approval from the National Medical Products Administration for its innovative drug, Zemeituosita Tablets (SHR2554), which is intended for adult patients with relapsed or refractory peripheral T-cell lymphoma (R/RPTCL) who have previously undergone at least one line of systemic therapy [2] Group 1 - The drug Zemeituosita Tablets is classified as a Class 1 innovative drug [2] - The approval is specifically for adult patients with R/RPTCL [2] - The drug is aimed at patients who have received at least one line of systemic treatment prior to this therapy [2]